Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-enhanced Ultrasound as a Diagnostic Tool by Chang, Emily H. et al.
Management of indeterminate cystic kidney lesions: Review of 
contrast-enhanced ultrasound as a diagnostic tool
Emily H. Changa, Wui K. Chongc, Sunny Kasojib, Paul A. Daytonb, and W. Kimryn Rathmelld
aDepartment of Medicine, Division of Nephrology and Hypertension, UNC Kidney Center, 
University of North Carolina at Chapel Hill
bBiomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State at 
Raleigh
cDepartment of Radiology, University of North Carolina at Chapel Hill
dDepartment of Medicine, Division of Hematology and Oncology, Lineberger Comprehensive 
Cancer Center, University of North Carolina at Chapel Hill
Abstract
Indeterminate cystic kidney lesions found incidentally on abdominal imaging are an increasingly 
prevalent diagnostic challenge. The standard workup includes Bosniak classification with contrast-
enhanced CT or MRI. However, these tests are costly and not without risks. Contrast-enhanced 
ultrasound (CEUS) is a relatively new imaging technique with lower risk of adverse events than 
iodine-containing contrast or gadolinium. In our review of the evidence for characterization of 
cystic kidney lesions with CEUS, CEUS displayed sensitivity (89–100%) and negative predictive 
value (86–100%) comparable to contrast-enhanced CT or MRI with no decrease in specificity 
compared to CT and only a slight decrease compared to MRI.
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INTRODUCTION
Due to a rise in abdominal imaging, particularly among chronic kidney disease patients and 
the elderly, increasingly physicians detect kidney cysts and other indeterminate lesions in the 
kidney. The best approach to these cystic lesions, sometimes referred to as “incidentalomas,” 
is not clear. The Bosniak classification system of kidney cysts, developed in 1986,1 classifies 
patients into categories (I, II, IIF, III and IV) based on lesion size and density, number, 
thickness and enhancement of septa, calcifications, and nodularity. Categories I and II are 
generally considered benign, IIF requires follow-up and III and IV are generally surgical 
lesions.
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The recommendation for Class IIF and III lesions, which make up the greatest proportion of 
complex cystic lesions, is to perform repeat or follow-up contrasted imaging studies which 
can often invoke patient anxiety and add to the burden of healthcare costs. Biopsy is an 
alternative, but poses risks to the patient and can be often be non-diagnostic. The tests used 
to follow indeterminate lesions suffer from serious limitations in certain patient populations. 
For example, these studies are contraindicated in patients with allergies to contrast agents, 
claustrophobia, or inability to lie flat or hold their breath. Most significantly, patients with 
moderate to severe renal insufficiency are both the highest risk group for developing 
complex lesions,2 and have the highest risk of morbidity and mortality from CT or MRI 
contrast agents. An ideal diagnostic imaging modality would have fewer of these adverse 
features but remain highly sensitive and specific in differentiating malignancy from benign 
disease.
More access to sensitive alternative imaging tools could improve management of these 
lesions and aid in the special at risk populations. Current alternative imaging approaches 
include several highly non-sensitive modalities: B-mode ultrasound, Doppler ultrasound, and 
unenhanced CT and MRI. Contrast enhanced ultrasound (CEUS) is also an emerging 
strategy that is being applied to these lesions. CEUS of the kidneys, initially introduced in 
1994,3 utilizes a microbubble contrast agent which, unlike CT and MRI agents, is not 
filtered through the glomeruli but remains intravascular, making CEUS ideal for visualizing 
tissue vascularity without opacifying the urinary tract or surrounding parenchyma. The 
contrast agents Sonovue, Definity and Optison are currently FDA approved only for cardiac 
use in the United States but approved for use in abdominal imaging outside the United States 
in Europe, India, China, South Korea and Brazil.
While a recent review of new imaging modalities for indeterminate cystic kidney lesions 
included CEUS,4 among other modalities, our review looks in depth at the evidence 
specifically related to CEUS, summarizing the current guidelines and diagnostic tools for 
characterizing cystic kidney lesions, reporting the existing evidence for application of CEUS 
to patients with indeterminate cystic kidney lesions, and comparing CEUS to conventional 
imaging modalities for cystic lesions to explore potential future clinical applications of 
CEUS in the kidney. To achieve this, we conducted a formal literature search with criteria 
shown in Supplemental Table 1. Our selection criteria were full-text, English language 
experimental studies in humans investigating CEUS for kidney lesions.
CURRENT CLINICAL GUIDELINES
While international urologic and radiologic associations provide guidelines for management 
of indeterminate cystic kidney lesions, numerous differences across societies exist. The 
major urologic associations advise use of contrast-enhanced CT as the primary test to 
characterize indeterminate cystic kidney lesions with contrast-enhanced MRI rated either 
equivalently or as a second option. The American College of Radiology rates contrast-
enhanced CT highest for those without kidney impairment while ratings for patients with 
kidney impairment are significantly different due to the nephrotoxic potential of contrast 
agents; subsequently, non-contrasted studies, though suboptimal, are relied upon 
(Supplemental Table 2).
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The current role of ultrasound in clinical guidelines is variable. The American Urologic 
Association does not specifically address indeterminate cystic lesions; guidelines are 
therefore extrapolated from sections on asymptomatic hematuria and stage T1 incidentally 
detected renal masses. They indicate the need for alternative, low-risk imaging methods, 
including screening ultrasound. Similarly, the British Association of Urologic Surgeons/
British Uro-oncology Group guidelines do not specifically address indeterminate cystic 
lesions, but in the guidelines for renal cancer, ultrasound is described as an initial screening 
modality. CEUS is mentioned only by the European Association of Urology, where SonoVue 
is approved for non-cardiac applications and more widely utilized than in the United States.
BOSNIAK CLASSIFICATION OF CYSTIC KIDNEY LESIONS
The rate of malignancy of cystic kidney lesions correlates with Bosniak classification. The 
classification scheme initially sorted cystic kidney lesions into 4 categories based on lesion 
complexity and thus likelihood of malignancy. Category I and II lesions are generally 
considered benign with very minimal chance of malignancy. Radiographically, Bosniak I 
lesions have non-enhancing thin walls with no septa or solid components. Bosniak II lesions 
have minimally enhancing hairline thin septa with fine to slightly thickened calcifications. 
Class II lesions also include completely intrarenal, marginated, non-enhancing cystic masses 
less than 3 cm. Category IV lesions are nearly 100% malignant warranting surgical removal 
in appropriate candidates. These lesions are cystic masses with enhancing soft tissue within 
the lesion and thickened, irregular and enhancing walls or septa. Many category III lesions 
were initially removed surgically but found to be benign, prompting the development of 
category IIF - lesions worrisome enough to warrant follow-up but not worrisome enough to 
warrant surgery.5 Management of these two categories, IIF and III, is the most challenging.
Category III lesions are generally accepted to be malignant 40–60% of the time,6, 7 
warranting surgical removal in the majority.7 These lesions have thickened, enhancing walls 
or septa with or without calcifications. Category IIF lesions have malignancy rates between 
5–25%6, 8, 9 and are generally followed with repeat imaging. These lesions are more 
complex than category II lesions with more septa and/or calcifications with minimal 
thickening and enhancement. This category also includes intrarenal, marginated, non-
enhancing cystic masses larger than 3 cm. Recommended duration and frequency of follow-
up is not clear and ranges from 1–5 years, depending on lesion complexity.9, 10 Repeated 
imaging with contrast-enhanced CT or MRI leads to high levels of radiation and/or contrast 
agent exposure, particularly an issue in younger patients. Therefore ultrasound is sometimes 
used, although CT or MRI remain the most accurate test. A summary of the current 
management strategy, based on Bosniak classification, is provided in Figure 1A.
IMAGING/DIAGNOSTIC APPROACHES TO CYSTIC KIDNEY LESIONS
A summary of the standard diagnostic approaches to indeterminate cystic kidney lesions is 
provided in Supplemental Table 3. A brief description of the current role for each modality 
is provided below.
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Conventional ultrasound with Doppler
As many as 83%11 of renal cell carcinomas (RCC) are revealed incidentally on conventional 
B-mode ultrasound. Conventional ultrasound is also an excellent test for simple cyst 
(Bosniak I and II) identification, but lacks diagnostic accuracy for complex cysts (Bosniak 
IIF, III and IV) as it provides no information on enhancement and small lesions < 2cm which 
are difficult to visualize. Currently, unenhanced ultrasound is most commonly used in 
patients with chronic kidney disease when contrast-enhanced CT or MRI is contraindicated 
and as a follow-up imaging modality.
Contrast-enhanced CT
Contrast-enhanced CT is the most commonly used imaging test for characterization of 
indeterminate kidney lesions and is the test on which the Bosniak criteria were initially 
based. Although there has been some variability reported regarding the reliability of the CT-
based Bosniak classification scheme,12 CT remains the first study recommended by both 
radiologic and urologic associations (Supplemental Table 2).
Contrast-enhanced MRI
Contrast-enhanced MRI is widely accepted as an alternative first-line study to characterize 
cystic kidney lesions. In direct comparisons, the two modalities showed similar findings in 
81% of cases. The differences primarily led to upgraded Bosniak classification with MRI 
based on findings of additional septa, wall thickness and enhancement.13
Biopsy
The utility of biopsy/aspiration in the diagnosis of complex cystic kidney lesions is not clear 
but is becoming more widely accepted as a way to spare patients unnecessary surgery.7, 14 
However, because there is less tissue to sample in a cystic lesion, there is a high chance of 
sampling error. Therefore a negative test will not necessarily exclude the need for 
surgery.15, 16 Moreover, instrumentation during biopsy can change the natural course of a 
lesion and its radiographic appearance, making follow-up studies challenging. Despite these 
limitations, the kidney biopsy literature reflects reasonable accuracy. For example, a study of 
312 lesions showed misclassification rate of only 2.25% based on CT-guided biopsy.17
CEUS TECHNOLOGY
Contrast-enhanced ultrasound consists of two components: an FDA approved intravenous 
microbubble contrast agent and ultrasound software capable of detecting contrast agents. 
The use of agitated saline as a contrast agent has been around for over 40 years.18 The basic 
principle is that gas microbubbles in the blood increase ultrasound scattering intensity, 
providing enhanced contrast between blood and surrounding tissue. However, gas bubbles 
from agitated saline dissolve quickly and do not pass the lungs, making agitated saline 
contrast useful for detecting right-to-left cardiac shunts (bubbles will not be visible in the 
left heart unless a shunt is present) but not useful as a contrast agent elsewhere in the 
circulation.
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The first generation of dedicated microbubble contrast agents was introduced in the 1990’s 
(Echovist by Schering, Levovist by Schering, Albunex by Molecular Biosystem).19 Lipid or 
albumin shells provide circulation persistence beyond agitated saline, but the high solubility 
of the air core in blood still led to rapid degradation. Newer generation agents utilize high 
molecular weight gas (Sulfur hexafluoride, Perfluoropropane, or Perfluorobutane) with 
lower solubility and greater stability in blood (Sonovue by Bracco Imaging, Definity by 
Lantheus Medical Imaging, Sonazoid by Daiichi Pharmaceutical/GE Healthcare, Optison by 
Mallinckrodt/GE Healthcare), increasing imaging time from seconds to minutes.19 Once 
dissolved, the gas is then exhaled through the lungs with no excretion through the liver or 
kidneys, making these agents safe for use in renal or hepatic insufficiency.
Although microbubble contrast agents can be visualized using traditional B-mode imaging, 
the difference between the microbubbles and surrounding tissue is minimal. Hence, modern 
ultrasound systems now utilize non-linear imaging techniques to differentiate the signal from 
tissue and microbubbles. Biological tissue produces a linear acoustic response. In contrast, 
microbubbles respond non-linearly, exhibiting differences in the way they respond to phase 
and amplitude of exciting pulses, as well as producing energy which contains 
subharmonics20 and harmonics21, 22 of the transmitted pulse that are not observed from 
tissue. This unique acoustic response allows for high sensitivity imaging of blood flow in 
small vessels.
In standard CEUS, a bolus of contrast is administered, typically 0.2–2 mL (depending on the 
manufacturer and concentration of bubbles in solution, patient mass, and imaging target) 
followed by 5–10 mL saline. A low mechanical index (MI) setting is typically used to avoid 
bubble destruction with continuous imaging.23 Real-time images are then obtained as the 
microbubbles flow through the region of interest. Qualitatively, features such as net 
enhancement, wash-in, and wash-out may be observed to provide an indication of 
vascularity and flow properties of the target tissue. Using cine clips and specialized 
software, time-intensity curves may be calculated from the change in image intensity to 
provide numerical values for wash-in rate, wash-out rate, or other quantitative parameters.
One of the advantages of CEUS is the low rate of serious adverse events with microbubble 
contrast agents, ranging from 0.009% to 0.014%,24, 25 significantly lower than gadolinium 
contrast. They are however contraindicated in the presence of right-to-left shunts, with 
caution recommended in certain cardiopulmonary conditions including recent acute 
myocardial infarction, severe heart failure, severe pulmonary hypertension, pregnancy and 
breastfeeding. Current ultrasound guidelines advise MI settings lower than 1.9, regardless of 
contrast use. Animal studies in which CEUS of the kidneys was performed show glomerular 
capillary hemorrhage and gross petechiae on the kidney surface with transient 
microhematuria.26 However, these studies used MIs higher than those used clinically for 
standard CEUS imaging.
One challenge to clinical application of CEUS is inter-operator and inter-observer 
variability. For example, ultrasonographers may choose different imaging windows, look at 
different angles, and choose different angles or imaging depths. The technique inherently 
requires more expertise and training to obtain high quality images than CT or MR. 
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Interpretation will also vary as radiologists are not used to reading this type of study. As 
with the implementation of any new technology, a significant amount of training and 
experience will be required.
COMPARISON OF CEUS vs. OTHER IMAGING MODALITIES
Our search strategy, displayed in Figure 2, identified 547 articles for full-text review after 
removal of duplicates, abstracts, reviews, case reports and commentaries. 532 full text 
articles were excluded based on selection criteria. A total of 15 full text articles were 
included in the final analysis. Nine of the 15 studies were not excluded by the search 
strategy but were not analyzed statistically because lesion inclusion criteria differed,27–30 
they used an ultrasound detection technique not optimized for contrast detection,31 or they 
focused on a specific subgroup or aspect of CEUS.32–35 These 9 studies provide valuable 
information and are summarized in supplemental table 4.
Of the remaining 6 studies, all included lesions were based on indeterminate findings on an 
imaging study and are presented in Table 1. While we attempted to limit the studies to those 
that included only cystic lesions, two studies did not specifically exclude solid lesions, 
although the percentage of solid lesions is low. Five of the six studies were conducted 
outside the US, due in large part to the approval for microbubble use in other countries.36–40 
Follow-up times varied, ranging from 12 months to 10 years, although most fell in the 2-year 
time frame.
From a technical standpoint, all studies used either SonoVue or Definity. Technique was 
similar, including a contrast agent volume of 1.2–2.4 mL, use of low MI, and contrast 
specific imaging techniques, including cadence pulse sequencing, harmonic imaging and 
pulse inverted harmonic imaging. Examples of a single image from cine clips obtained with 
CEUS are shown in figures 1B and C. For most studies, the contrast-enhanced CT based 
Bosniak criteria were used for lesion characterization. Septa and wall enhancement were the 
main lesion characteristics detected on CEUS that contributed to Bosniak classification. All 
studies except one41 used multiple readers to address inter-observer variability.
Due to challenges such as variable follow-up time, different ways of controlling for 
variability between readers, and the fine gradation of the Bosniak classification system, 
uniform interpretation of the studies as presented was not possible. In calculations of 
sensitivity, specificity, positive and negative predictive values, we thus placed Bosniak I, II 
and IIF into the negative category and Bosniak III and IV into positive category as this is the 
delineation between primarily non-surgical and surgical lesions. One drawback to this 
strategy is that a change in classification from Bosniak I to IIF would not be detected based 
on this strategy. This was deemed acceptable, as it would not greatly affect clinical 
management. Any follow-up of at least a year was accepted.
The most notable and consistent finding across the six studies was the high sensitivity of 
CEUS for detection of malignant cystic kidney lesions. Sensitivity ranged from 89–100% 
and reached 100% in three studies,36, 37, 41 including the large, US-based study with over 
900 cystic lesions.41 This is attributed to the ability of CEUS to detect subtle enhancement 
Chang et al. Page 6
Urology. Author manuscript; available in PMC 2017 July 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
in thin septa that are more difficult to detect with either CT or MRI. Although not reflected 
in the statistics, upgrade of Bosniak classification from I/II to IIF also occurred with CEUS, 
due to increased sensitivity in detection of enhancement.
Specificity was moderate with CEUS, ranging from 71–99%. This was due in large part to 
false positives. As reported by Ascenti, of five false positives, two were inflammatory cysts, 
one was xanthogranulomatous pyelonephritis, one was multilocular cystic RCC (an indolent 
malignancy) and one refused intervention and was stable at 18-month follow-up. The false 
positive findings reported by Clevert were all Bosniak III and also reported as false positives 
by contrast-enhanced CT. Compared to MRI, CEUS had a higher false positive rate with 10 
out of 35 benign lesions being misdiagnosed by CEUS and only 8 out of 35 being 
misdiagnosed by MRI. These consisted primarily of benign cystic kidney lesions and 
angiomyolipomas.
Negative predictive value was also consistently high between the studies, ranging from 86–
100%. Because both per study cost and risks associated with CEUS are lower than either CT 
or MRI, with a high negative predictive value, use of CEUS prior to CT or MRI could limit 
the number of costly, potentially harmful studies. However, positive findings would still 
likely require further evaluation by either CT, MRI or biopsy. But routine use of CEUS has 
the potential to significantly alter management both for individual patients and for the field 
as a whole.
SPECIALIZED TOPICS
The remaining 9 studies were not excluded based on any of the named exclusion criteria but 
did not specifically compare the overall diagnostic accuracy of CEUS compared to other 
modalities. Thus they were not included in the formal analysis. However, they do provide 
useful information that can inform development of the technology for clinical use. A 
summary is provided in Supplemental Table 4.
In studies that included patients based on histologic diagnosis,27–30 sensitivity was 
comparable to the 6 main studies (80–100%). However, specificity was decreased, likely due 
to inclusion criteria. The vast majority of cases were malignant lesions, as these were most 
likely to be resected or biopsied, resulting in omission of numerous true negative cases and 
leading to a wide range in specificity (0–80%). Although false negative cases might also be 
absent, skewing sensitivity, all studies had at least one other imaging study, usually contrast-
enhanced CT. Therefore, decision to resect was based on these studies and the lesion would 
not have been detected, even with the current standard of care.
The ability of CEUS to predict histologic subtype has also been investigated with minimal 
success thus far. There is certainly ability to differentiate a solid from a cystic lesion32 and 
define necrotic areas from solid carcinoma or cystic regions.33 However, correlation of 
enhancement patterns with histologic subtype, i.e. clear cell, papillary cell or multilocular 
cystic RCC, has not yet been clearly defined.35 Whether CEUS can predict histologic 
subtype and thus help with prognostication, is yet to be determined.
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Inclusion of the specific population that might benefit most from CEUS, chronic kidney 
disease patients, has not yet been conducted. However, a subgroup of this population, renal 
transplant patients with acquired cystic kidney disease, has been studied.42 This patient 
population is clinically relevant, both because of their increased risk for cancer but also 
because contrasted CT or MRI is often avoided in these patients. In a cohort of 43 renal 
transplant patients with acquired cystic kidney disease, 35 lesions were detected in the native 
kidneys of 15 patients on conventional ultrasound.34 Each lesion was subsequently evaluated 
with CEUS. Twenty-seven lesions were classified as Bosniak I or II based on CEUS; four 
lesions were classified as Bosniak III or IV. Those four lesions underwent contrast-enhanced 
CT followed by surgical resection with confirmed cancer in 100%.
FUTURE DIRECTIONS
Numerous other applications for CEUS in the kidneys have been investigated, including 
trauma, pyelonephritis, ischemia and renal artery stenosis.43 Additionally, even more 
applications are under current investigation. Post-surgical surveillance after nephron sparing 
surgery, peri-operational use to aid surgical location and complete resection, and peri-
procedural monitoring during radiofrequency ablation44 are three such applications. The 
sensitivity of CEUS can also be very useful to detect recurrence of disease and spare patients 
repeated exposure to radiation and costly tests. In addition, in experimental models of anti-
angiogenic drug therapies, the use of CEUS may track response to therapy.45
In other applications, molecular ultrasound imaging with targeted microbubbles is being 
explored as a way to further increase diagnostic accuracy and ability to detect inflammation, 
thrombus, microvascular changes associated with early diabetic nephropathy46 and other 
vascular phenomena with sensitivity beyond CT or MRI. Microbubbles are also being 
investigated as a way to deliver drug or gene therapy to a specific organ, reducing potential 
toxic effects to other organs.22, 46
In addition to characterizing renal lesions, characterization of enhancement of renal 
parenchyma is also an area with potential clinical impact. Loss of vascularization of the 
failing kidney occurs throughout the course of chronic kidney disease. The ability to detect 
changes in perfusion in kidneys with a minimally invasive imaging technique may help 
clinicians detect patients with early stages of chronic kidney disease and target them for 
early interventions.
CONCLUSIONS
CEUS has potential to become an option as an initial diagnostic test for indeterminate cystic 
kidney lesions. The high sensitivity and negative predictive value, along with its excellent 
adverse effect profile and low cost, make it a candidate for a first line test. One challenge to 
widespread CEUS adoption is the current lack of experience by technicians and radiologists. 
Standardized CEUS administration and interpretation protocols and specialized training in 
this modality are needed. The potential payoff, in terms of patient safety and potential 
healthcare dollars saved, though, may be well worth the effort.
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A proposed management strategy is shown in Figure 1D. However, more large, multi-center 
trials comparing CEUS to the current standard along with analysis of cost benefits are 
needed. CEUS also has potential to be utilized as the follow-up imaging study of choice for 
Bosniak IIF and III lesions for which patients opt to manage with surveillance as there 
would be significantly lower exposure to radiation from repeated imaging. Efforts made by 
the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) 
and The International Contrast Ultrasound Society (ICUS) to encourage appropriate 
utilization of CEUS are supported by the authors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A. Current management strategy for indeterminate cystic kidney lesions
B. CEUS image from a patient with polycystic kidney disease. Conventional gray-scale 
ultrasound images are on the right, single time point contrast-enhanced images are on the 
left. Arrows point to the lesion wall and septa that clearly enhance with CEUS but are 
difficult to detect with gray-scale ultrasound. This was classified as a Bosniak III lesion by 
CEUS.
C. CEUS image from a patient with renal cell carcinoma. Conventional gray-scale 
ultrasound images are on the right, single time point contrast-enhanced images are on the 
left. The circle encloses the enhancing solid portion of this lesion that is difficult to 
differentiate from surrounding parenchyma on gray-scale ultrasound. This was classified as 
a solid renal lesion by CEUS.
D. Proposed management strategy for indeterminate cystic kidney lesions seen on 
conventional ultrasound
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Figure 2. 
Flow chart for search strategy
* Only 6 of the articles are included in table 3. The remaining 9 articles are reviewed and 
included in supplemental table 2.
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